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ABSTRACT
ObjeCtives
To reanalyse SmithKline Beecham’s Study 329 
(published by Keller and colleagues in 2001), the 
primary objective of which was to compare the efficacy 
and safety of paroxetine and imipramine with placebo 
in the treatment of adolescents with unipolar major 
depression. The reanalysis under the restoring invisible 
and abandoned trials (RIAT) initiative was done to see 
whether access to and reanalysis of a full dataset from 
a randomised controlled trial would have clinically 
relevant implications for evidence based medicine.
Design
Double blind randomised placebo controlled trial.
setting
12 North American academic psychiatry centres, from 
20 April 1994 to 15 February 1998.
PartiCiPants
275 adolescents with major depression of at least 
eight weeks in duration. Exclusion criteria included a 
range of comorbid psychiatric and medical disorders 
and suicidality.
interventiOns
Participants were randomised to eight weeks double 
blind treatment with paroxetine (20-40 mg), 
imipramine (200-300 mg), or placebo.
Main OutCOMe Measures
The prespecified primary efficacy variables were 
change from baseline to the end of the eight week 
acute treatment phase in total Hamilton depression 
scale (HAM-D) score and the proportion of responders 
(HAM-D score ≤8 or ≥50% reduction in baseline HAM-D) 
at acute endpoint. Prespecified secondary outcomes 
were changes from baseline to endpoint in depression 
items in K-SADS-L, clinical global impression, 
autonomous functioning checklist, self-perception 
profile, and sickness impact scale; predictors of 
response; and number of patients who relapse during 
the maintenance phase. Adverse experiences were to 
be compared primarily by using descriptive statistics. 
No coding dictionary was prespecified.
results
The efficacy of paroxetine and imipramine was not 
statistically or clinically significantly different from 
placebo for any prespecified primary or secondary 
efficacy outcome. HAM-D scores decreased by 10.7 
(least squares mean) (95% confidence interval 9.1 to 
12.3), 9.0 (7.4 to 10.5), and 9.1 (7.5 to 10.7) points, 
respectively, for the paroxetine, imipramine and 
placebo groups (P=0.20). There were clinically 
significant increases in harms, including suicidal 
ideation and behaviour and other serious adverse 
events in the paroxetine group and cardiovascular 
problems in the imipramine group.
COnClusiOns
Neither paroxetine nor high dose imipramine showed 
efficacy for major depression in adolescents, and there 
was an increase in harms with both drugs. Access to 
primary data from trials has important implications for 
both clinical practice and research, including that 
published conclusions about efficacy and safety 
should not be read as authoritative. The reanalysis of 
Study 329 illustrates the necessity of making primary 
trial data and protocols available to increase the rigour 
of the evidence base.
Introduction
In 2013, in the face of the selective reporting of outcomes 
of randomised controlled trials, an international group of 
researchers called on funders and investigators of aban-
doned (unpublished) or misreported trials to publish 
undisclosed outcomes or  correct misleading publica-
tions.1 This initiative was called “restoring invisible and 
abandoned trials” (RIAT). The researchers identified 
many trials requiring restoration and emailed the funders, 
asking them to signal their intention to publish the unpub-
lished trials or publish corrected versions of misreported 
trials. If funders and investigators failed to undertake to 
correct a trial that had been identified as unpublished or 
misreported, independent groups  were encouraged to 
publish an accurate  representation of the clinical trial 
based on the relevant regulatory information.
The current article represents a RIAT publication 
of  Study 329. The original study was funded by 
WhAT IS AlReAdy knoWn on ThIS TopIC
There is a lack of access to data from most clinical randomised controlled trials, 
making it difficult to detect biased reporting
In the absence of access to primary data, misleading conclusions in publications of 
those trials can seem definitive
SmithKline Beecham’s Study 329, an influential trial that reported that paroxetine 
was safe and effective for adolescents, is one such study
WhAT ThIS STudy AddS
On the basis of access to the original data from Study 329, we report a reanalysis 
that concludes that paroxetine was ineffective and unsafe in this study
Access to primary data makes clear the many ways in which data can be analysed 
and represented, showing the importance of access to data and the value of 
reanalysis of trials
There are important implications for clinical practice, research, regulation of trials, 
licensing of drugs, and the sociology and philosophy of science
Our reanalysis required development of methods that could be adapted for future 
reanalyses of randomised controlled trials
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SmithKline Beecham (SKB; subsequently GlaxoSmith-
Kline, GSK). We acknowledge the work of the original 
investigators. This double blinded randomised con-
trolled trial to evaluate the efficacy and safety of parox-
etine and imipramine compared with placebo for 
adolescents diagnosed with major depression was 
reported in the Journal of the American Academy of 
Child and Adolescent Psychiatry (JAACAP) in 2001, with 
Martin Keller as the primary author.2  The RIAT 
researchers identified Study 329 as an example of a 
misreported trial in need of restoration. The article by 
Keller and colleagues, which was largely ghostwritten,3 
claimed efficacy and safety for paroxetine that was at 
odds with the data.4  This is problematic because the 
article has been influential in the literature supporting 
the use of antidepressants in adolescents.5
On 14 June 2013, the RIAT researchers asked GSK 
whether it had any intention to restore any of the trials 
it sponsored, including Study 329. GSK did not signal 
any intent to publish a corrected version of any of its 
trials. In later correspondence, GSK stated that the 
study by Keller and colleagues “accurately reflects the 
honestly-held views of the clinical investigator authors” 
and that GSK did “not agree that the article is false, 
fraudulent or misleading.”6
Study 329 was a multicentre eight week double blind 
randomised controlled trial (acute phase), followed by a 
six month continuation phase. SKB’s stated primary 
objective was to examine the efficacy and safety of imip-
ramine and paroxetine compared with placebo in the 
treatment of adolescents with unipolar major depres-
sion. Secondary objectives were to identify predictors of 
treatment outcomes across clinical subtypes; to provide 
information on the safety profile of paroxetine and imip-
ramine when these drugs were given for “an extended 
period of time”; and to estimate the rate of relapse among 
patients who responded to imipramine, paroxetine, and 
placebo and were maintained on treatment. Study enrol-
ment took place between April 1994 and March 1997.
The first RIAT trial publication was a surgery trial that 
had been only partly published before.7  Few previously 
published randomised controlled trials have ever been 
subsequently reported in published papers by different 
teams of authors.8
Methods
We reanalysed the data from Study 329 according to the 
RIAT recommendations. To this end, we used the clini-
cal study report (SKB’s “final clinical report”), including 
appendices A-G, which are publically available on the 
GSK website,9  other publically available documents,10 
and the individual participant data accessed through 
SAS Solutions OnDemand website,11  on which GSK sub-
sequently also posted some Study 329 documents (avail-
able only to users approved by GSK). After negotiation,12 
GSK posted about 77 000 pages of de-identified individual 
case report forms (appendix H) on that website. We used 
a tool for documenting the transformation from regula-
tory documents to journal publication, based on the CON-
SORT 2010 checklist of information to include when 
reporting a randomised trial. The audit record, includ-
ing a table of sources of data consulted in preparing 
each part of this paper, is available in appendix 1.
Except where indicated, in accordance with RIAT 
 recommendations, our methods are those set out in the 
1994-96 protocol for Study 329.13 In cases when the meth-
ods used and published by Keller and colleagues diverged 
from the protocol, we followed the original protocol. 
Because the protocol specified method of correction for 
missing values—last observation carried forward—has 
been questioned in the intervening years, we also 
included a more modern method—multiple imputation—
at the request of the BMJ peer reviewers. This is a post hoc 
method added for comparison only and is not part of our 
formal reanalysis. When the protocol was not specific, we 
chose by consensus standard methods that best pre-
sented the data. The original 1993 protocol had minor 
amendments in 1994 and 1996 (replacement of the 
 Schedule for Affective Disorders and Schizophrenia for 
Adolescents-Present Version with the Lifetime Version 
(K-SADS-L) and reduction in required sample size). Fur-
thermore, the clinical study report (CSR) reported some 
procedures that varied from those specified in the proto-
col. We have noted variations that we considered relevant.
Participants
The original study recruited 275 adolescents aged 12-18 
who met DSM-IV criteria14 for a current episode of 
major depression of at least eight weeks’ duration 
(the  protocol specified DSM-III-R criteria, which are 
 similar). Box 1 lists the eligibility criteria.
An unknown number of patients (not disclosed in the 
available documents) identified by telephone screening 
as potential participants were subsequently evaluated 
box 1 study eligibility criteria
inclusion criteria
•	Adolescents aged 12-18 who met DSM-III-R criteria for major depression for at least 
8 weeks
•	Severity score <60 on the children’s global assessment scale (CGAS)
•	Score ≥12 on the Hamilton depression scale (17 item) (HAM-D)
•	Medically healthy
•	 IQ ≥80 (based on Peabody picture vocabulary test)
exclusion criteria
•	Current or past DSM-III-R diagnosis of bipolar disorder, schizoaffective disorder, 
anorexia nervosa, bulimia, alcohol or drug abuse/dependence, obsessive-
compulsive disorder, autism/pervasive mental disorder, or organic psychiatric 
disorder
•	Current (within 12 months) DSM-III-R diagnosis of post-traumatic stress disorder
•	Adequate trial of an antidepressant within six months (at least four weeks’ 
treatment with an adequate dose of antidepressant)
•	Suicidal ideation with a definite plan, suicide attempt during current depressive 
episode, or history of suicide attempt by drug overdose
•	Medical illness that contraindicates the use of heterocyclic antidepressants
•	Current use of psychotropic drugs (including anxiolytics, antipsychotics, mood 
stabilisers), or illicit drugs
•	Organic brain disease, epilepsy, or “mental retardation”
•	Pregnancy or lactation
•	Sexually active females not using reliable contraception
•	Use of an investigational drug within previous 30 days or five half lives of the 
investigation drug
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at the study site by a senior clinician (psychiatrist or 
psychologist). Multiple meetings and teleconferences 
were held by the sponsoring company with site study 
investigators to ensure standardisation across sites. 
Patients and parents were interviewed separately with 
the K-SADS-L. After this initial assessment, the patient 
and parent both signed the study informed consent 
form; there was no mention of a separate assent form in 
the protocol or in the CSR. A screening period of seven 
to ten days was used to obtain past clinical records and 
to document that the depressive symptoms were stable. 
At the end of the screening period, only patients con-
tinuing to meet the inclusion criteria (DSM-III-R major 
depression and the HAM-D total score ≥12) were ran-
domised. There was no placebo lead-in phase.
There were originally six study sites, but this was 
increased to 12 (10 in the United States and two in Can-
ada). The centres were affiliated with either a university 
or a hospital psychiatry department and had experi-
ence with adolescent patients. The investigators were 
selected for their interest in the study and their ability 
to recruit study patients.
The recruitment period ran from 20 April 1994 until 15 
March 1997, and the acute phase was completed on 7 
May 1997. In a small number of patients, 30 day fol-
low-up data for cases that went into the continuation 
phase were collected into February 1998.
Patient involvement
So far as we can ascertain, there was no patient involve-
ment in SKB’s study design.
interventions
The study drug was provided to patients in weekly blis-
ter packs. Patients were instructed to take the drug 
twice daily. There were six dosing levels. Over the first 
four weeks, all patients were titrated to level four, corre-
sponding to 20 mg paroxetine or 200 mg imipramine, 
regardless of response. Non-responders (those failing to 
reach responder criteria) could be titrated up to level 
five or six over the next four weeks. This corresponds to 
maximum doses of 60 mg paroxetine and 300 mg imip-
ramine.
Compliance with treatment was evaluated from the 
number of capsules dispensed, taken, and returned. 
Non-compliance was defined as taking less than 80% or 
more than 120% of the number of capsules, assessed 
from the numbers expected to be returned at two con-
secutive visits, and resulted in withdrawal. Any patient 
missing two consecutive visits was also withdrawn from 
the study.
Patients were provided with 45 minute weekly ses-
sions of supportive psychotherapy,15 primarily for the 
purpose of assessing the effects of treatment.
sample size
The acute phase of the trial was initially based on a 
power analysis that indicated that a sample size of 100 
patients per treatment group was required to have a sta-
tistical power of 80% for a two tailed α of 0.05 and an 
effect size of 0.40. This effect size entailed a difference 
of 4 in the HAM-D total score from baseline to endpoint, 
specified in the protocol to be large enough to be clini-
cally meaningful, considering a standard deviation of 
10. No allowance was made in the power calculation for 
attrition (anticipated dropout rate) or non-compliance 
during the study.
Recruitment was slower than expected, and report-
edly supplies of treatment (mainly placebo) ran short 
due to exceeding the expiry date. The researchers car-
ried out a midcourse evaluation of 189 patients, without 
breaking the blinding, which showed less variability in 
HAM-D scores (SD 8) than expected. Therefore the 
recruitment target was reduced to 275 on the grounds 
that it would have no negative impact on the estimated 
80% power required to detect a 4 point difference 
between placebo and active drug groups.
randomisation
A computer generated randomisation list of 360 num-
bers for the acute phase was generated and held by 
SKB. According to the CSR, treatments were balanced in 
blocks of six consecutive patients; however, there is an 
inconsistency in that appendix A randomisation code 
details block sizes of both six and eight. Each investiga-
tor was allocated a block of consecutively numbered 
treatment packs, and patients were assigned treatment 
numbers in strict sequential order. Patients were ran-
domised in a 1:1:1 ratio to treatment with paroxetine, 
imipramine, or placebo.
blinding
Paroxetine was supplied as film coated, capsule shaped 
yellow (10 mg) and pink (20 mg) tablets. Imipramine 
(50 mg) was bought commercially and supplied as 
green film coated round 50 mg tablets. “Paroxetine pla-
cebos” matched the paroxetine 20 mg tablets, and 
“imipramine placebos” matched the imipramine tab-
lets. All tablets were over-encapsulated in bluish-green 
capsules to preserve blinding.
The blinding was to be broken only in the event of a 
serious adverse event that the investigator thought 
could not be adequately treated without knowing the 
identity of the allocated study treatment. The identity of 
the study treatment was not otherwise to be disclosed to 
the investigator or SKB staff associated with the study.
Outcomes
Patients were evaluated weekly for the following out-
come variables during the eight week duration of the 
acute treatment phase.
Primary efficacy variables
The prespecified primary efficacy variables were 
change in total score on HAM-D16 from the beginning 
of the treatment phase to the endpoint of the acute 
phase and the proportion of responders at the end of 
the eight week acute treatment phase (longer than 
many antidepressant trials). Responders were defined 
as patients who had ≥50% reduction in the HAM-D or 
a HAM-D score of ≤8. (Scores on the HAM-D can vary 
from 0 to 52.)
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Secondary efficacy variables
The prespecified secondary efficacy variables were:
•	 Changes from baseline to endpoint in:
 Depression items in K-SADS-L
 Clinical global impression (CGI)
 Autonomous functioning checklist17
 Self perception profile
 Sickness impact scale.
•	 Predictors of response (endogenous subtypes, age, 
previous episodes, duration and severity of present 
episode, comorbidity with separate anxiety, atten-
tion deficit, and conduct disorder)
•	 The number of patients who relapsed during the 
maintenance phase (referred to in the CSR and in this 
paper as “continuation phase”).
Both before and after breaking the blind, however, 
the sponsors made changes to the secondary outcomes 
as previously detailed.4  We could not find any docu-
ment that provided any scientific rationale for these 
post hoc changes,18 and the outcomes are therefore not 
reported in this paper.
Challenges in carrying out riat
To our knowledge this is the first RIAT analysis of a mis-
reported trial by an external team of authors, so there 
are no clear precedents or guides. Challenges we have 
encountered included:
Potential or perceived bias
A RIAT report is not intended to be a critique of a previ-
ous publication. The point is rather to produce a thor-
ough independent analysis of a trial that has remained 
unpublished or called into question. We acknowledge, 
however, that any RIAT team might be seen as having an 
intrinsic bias in that questioning the earlier published 
conclusions is what brought some members of the team 
together. Consequently, we took all appropriate proce-
dural steps to avoid such putative bias. In addition, we 
have made the data available for others to analyse. 
Correction for testing multiple variables
We had multiple sources of information: the protocol; 
the published paper; the documents posted on the GSK 
website including the CSR and individual patient data; 
and the raw primary data in the case report forms pro-
vided by GSK on a remote desktop for this project. The 
protocol declared two primary and six secondary vari-
ables for the three treatment groups in two differing 
datasets (observed case and last observation carried 
forward). The CSR contained statistical comparisons on 
28 discrete variables using two comparisons (paroxe-
tine v placebo and imipramine v placebo) in the two 
datasets (observed case and last observation carried 
forward). The published paper listed eight variables 
with two statistical comparisons each in one dataset 
(last observation carried forward). The authors of the 
original paper, however, did not deal with the need for 
corrections for multiple variables—a standard require-
ment when there are multiple outcome measures. In the 
final analysis, there were no statistically or clinically 
significant findings for any outcome variable, so correc-
tions were not needed for this analysis.
Statistical testing 
The protocol called for ANOVA testing (generalised lin-
ear model) for continuous variables using a model that 
included the effects of site, treatment, and site × treat-
ment interaction, with the latter dropped if P≥0.10. 
Logistical regression (2×3 χ2) was prescribed for cate-
gorical variables under the same model. Both methods 
begin with an omnibus statistic for the overall signifi-
cance of the dataset, then progress to pairwise testing 
if, and only if, the omnibus statistic meets α=0.05. 
Yet all statistical outcomes in the CSR and published 
paper were reported only as the pairwise values for only 
two of the three possible comparisons (paroxetine v pla-
cebo and imipramine v placebo), with no mention of the 
omnibus statistic. Therefore, we conducted the required 
omnibus analyses, with negative results as shown. The 
pairwise values are available in table A in appendix 2.
Missing values
The protocol called for evaluation of the observed case 
and last observation carried forward datasets, with the 
latter being definitive. The last observation carried for-
ward method for correcting missing values was the 
standard at the time the study was conducted. It contin-
ues to be widely used, although newer models such as 
multiple imputation or mixed models are superior. 
We  chose to adhere to the protocol and use the last 
 observation carried forward method, including multi-
ple imputation for comparison only.
Outcome variables not specified in protocol
There were four outcome variables in the CSR and in 
the published paper that were not specified in the proto-
col. These were the only outcome measures reported as 
significant. They were not included in any version of the 
protocol as amendments (despite other amendments), 
nor were they submitted to the institutional review board. 
The CSR (section 3.9.1) states they were part of an “analy-
sis plan” developed some two months before the blinding 
was broken. No such plan appears in the CSR, and we 
have no contemporaneous documentation of that claim, 
despite having repeatedly requested it from GSK.
Conclusions
We decided that the best and most unbiased course of 
action was to analyse the efficacy data in the individual 
patient data based on the last guaranteed a priori ver-
sion of SKB’s own protocol (1994, amended in 1996 to 
accept a reduced sample size). Although the protocol 
omitted a discussion of corrections that we would have 
thought necessary, correction for multiple variables is 
designed to prevent false positives and there were no 
positives. We agreed with the statistical mandates of the 
protocol, but though we regarded pairwise comparisons 
in the absence of overall significance as inappropriate, 
we recognise that this is not a universal opinion, so we 
included the data in table A in appendix 2.
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Finally, although investigators can explore the data 
however they want, additional outcome variables out-
side those in the protocol cannot be legitimately declared 
once the study is underway, except as “exploratory vari-
ables”—appropriate for the discussion or as material for 
further study but not for the main analysis. The a priori 
protocol and blinding are the bedrock of a randomised 
controlled trial, guaranteeing that there is not even the 
possibility of the HARK phenomenon (“hypothesis after 
results known”). Though we can readily show that none 
of the reportedly “positive” four non-protocol outcome 
variables stands up to scrutiny, the primary mandate of 
the RIAT enterprise is to reaffirm essential practices in 
randomised controlled trials, so we did not include these 
variables in our efficacy analysis.
Harm endpoints
An adverse experience/event was defined in the proto-
col (page 18) as “any noxious, pathologic or unintended 
change in anatomical, physiologic or metabolic func-
tions as indicated by physical signs, symptoms and/or 
laboratory changes occurring in any phase of the clini-
cal trial whether associated with drug or placebo and 
whether or not considered drug related. This includes 
an exacerbation of pre-existing conditions or events, 
intercurrent illnesses, drug interaction or the signifi-
cant worsening of the disease under investigation that 
is not recorded elsewhere in the case report form under 
specific efficacy assessments.”
Adverse events were to be elicited by the investigator 
asking a non-leading question such as: “Do you feel dif-
ferent in any way since starting the new treatment/the 
last assessment?” Details of adverse events that 
emerged with treatment, their severity, including any 
change in study drug administration, investigator attri-
bution to study drug, any corrective therapy given, and 
outcome status were documented. Attribution or rela-
tion to study drug was judged by the investigator to be 
“unrelated,” “probably unrelated,” “possibly related,” 
“probably related,” or “related.”
Vital signs and electrocardiograms were obtained at 
weekly visits. Patients with potentially concerning car-
diovascular measures either had their drug dose 
reduced or were withdrawn from the study. In addition, 
if the combined serum concentrations (obtained at 
weeks four and eight) of imipramine and desipramine 
exceeded 500 µg/mL the patient was to be withdrawn 
from the study.
Clinical laboratory tests, including clinical chemis-
try, haematology, and urinalysis, were carried out at the 
screening visit and at the end of week eight. Clinically 
relevant laboratory abnormalities were to be included 
as adverse events.
source of harms data
The harms data in this paper cover the acute phase, a 
taper period, and a follow-up phase of up to 30 days for 
those who discontinued treatment because of adverse 
events. To ensure comparability with the report by 
Keller and colleagues, none of the tables contains data 
from the continuation phase.
Data on adverse events come from the CSR lodged on 
GSK’s website,19 primarily in appendix D. Appendix B 
provides details of concomitant drugs. Additional infor-
mation was available from the summary narratives in 
the body of the CSR for patients who had adverse events 
that were designated as serious or led to withdrawal. 
(Of the 11 patients taking paroxetine who experienced 
adverse events designated as serious, nine discontin-
ued treatment because of these events.) The large num-
ber of other patients discontinued because of adverse 
events that were not regarded as serious, or discontin-
ued for lack of efficacy or protocol violations, however, 
did not generate patient narratives. The tables in 
appendix D of the CSR provide the verbatim terms used 
by the blinded investigators, along with preferred terms 
as coded by SKB using the adverse drug events coding 
system (ADECS) dictionary. Appendix D also includes 
ratings of severity and ratings of relatedness. We used 
the Medical Dictionary for Regulatory Activities (Med-
DRA) to code the verbatim terms provided in appendix D 
in the CSR. MedDRA terminology is the international 
medical terminology developed under the auspices of 
the International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceu-
ticals for Human Use (ICH) www.meddra.org), endorsed 
by the FDA, and now used by GSK.20
Several limitations of the ADECS coded preferred 
terms provided in appendix D of the CSR became clear 
when we examined the ADECS preferred terms assigned 
to the verbatim terms. Firstly, several verbatim terms 
had been left uncoded into ADECS. Secondly, several 
adverse events found in the patient narratives of serious 
adverse events that led to discontinuation from the trial 
were not transcribed into appendix D.
We therefore approached GSK for access to case 
report forms (appendix H of the CSR), which are not 
publically available. GSK made available all 275 case 
report forms for patients entered into Study 329. These 
forms, however, which totalled about 77 000 pages, 
were available only through a remote desktop facility 
(SAS Solutions OnDemand Secure Portal),11  which 
made it difficult and extremely time consuming to 
inspect the records properly.21 Effectively only one per-
son could undertake the task, with backup for ambigu-
ous cases. Accordingly we could not examine all case 
report forms. Instead we decided to focus on those 85 
participants identified in appendices D and G of the CSR 
who were withdrawn from the study, along with eight 
further participants who were known from our inspec-
tion of the CSRs to have become suicidal. Of the case 
report forms that were checked, 31 were from the parox-
etine group, 40 from the imipramine group, and 22 from 
the placebo group.
All case report forms were reviewed by JLN, who was 
trained in the use of MedDRA. The second reviewer 
(JMN), a clinician, was not trained in the MedDRA 
 system, but training is not necessary for coding of 
 dropouts. These two reviewers agreed about reasons 
for discontinuation and coding of side effects (we did 
not use a quantitative indicator of agreement between 
raters). We scrutinised these 93 case report forms for all 
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adverse events occurring during the acute, taper, and 
follow-up phases, and compared our totals for adverse 
events with the totals reported in appendix D of the 
CSR. This review process identified additional adverse 
events that had not been recorded as verbatim terms in 
appendix D of the CSR. It also led to recoding of several 
of the reasons for discontinuation. Tables B, C, and H in 
appendix 2 show the new adverse events and the rea-
sons for changing the discontinuation category.
At least 1000 pages were missing from the case report 
forms we reviewed, with no discernible pattern to miss-
ing information—for example, one form came with a 
page inserted stating that pages 114 to 223 were missing, 
without indicating reasons.
Coding of adverse events
Choice of coding dictionary for harms
The protocol (page 25) indicates that adverse events 
were to be coded and compared by preferred term and 
body system by using descriptive statistics but does not 
prespecify a choice of coding dictionary for generating 
preferred terms from verbatim terms. The CSR (written 
after the study ended) specifies that the adverse events 
noted by clinical investigators in this trial were coded 
with ADECS, which was being used by SKB at the time. 
This system was derived from a coding system devel-
oped by the US Food and Drug Administration (FDA), 
Coding Symbols for a Thesaurus of Adverse Reaction 
Terms (COSTART), but ADECS is not itself a recognised 
system and is no longer available.
We coded adverse events using MedDRA, which has 
replaced COSTART for the FDA because it is by far the 
most commonly used coding system today. For coding 
purposes, we have taken the original terms used by the 
clinical investigators, as transcribed into appendix D 
of the CSR, and applied MedDRA codes to these 
descriptions. Information from appendix D was tran-
scribed into spreadsheets (available at www.Study329.
org). The verbatim terms and the ADECS coding terms 
were transcribed first into these sheets, allowing all 
coding to be done before the drug names were added 
in. The transcription was carried out by a research 
assistant who was a MedDRA trained coder but took 
no part in the actual coding. All coding was carried out 
by JLN, and checked by DH, or vice versa. All of our 
coding from the verbatim terms in the appendix D of 
the CSR was done blind, as was coding from the case 
report forms.
We present results as SKB presented them in the CSR 
using the ADECS dictionary (table 14.2.1), and as coded 
by us using MedDRA. In general, MedDRA coding stays 
closer than ADECS to the original clinician description 
of the event. For instance, MedDRA codes “sore throat” 
as “sore throat” but SKB, using ADECS, coded it as 
“pharyngitis” (inflammation of the throat). Sore throats 
can arise because of pharyngitis, but when someone is 
taking selective serotonin reuptake inhibitors they can 
indicate a dystonic reaction in the oropharyngeal area.22
Classification of a problem as a “respiratory system 
disorder” (inflammation) rather than as a “dystonia” 
(a central nervous system disorder) can make a consid-
erable difference to the apparent adverse event profile 
of a drug. In staying closer to the original description of 
events, MedDRA codes suicidal events as “suicidal ide-
ation” or “self harm/attempted suicide” rather than the 
ADECS option of “emotional lability”; similarly, aggres-
sion is more clearly flagged as “aggressive events” 
rather than “hostility.”
Most coding was straightforward. Nearly all the verba-
tim terms simply mapped onto coding terms in MedDRA. 
Coding challenges usually related to cases where there 
were significant adverse events but the patients were 
designated by SKB to have discontinued for lack of effi-
cacy. There was no patient narrative for such patients, in 
contrast to patients deemed to have discontinued 
because of the adverse event occurring at discontinua-
tion. There were few challenging coding decisions. 
Appendix 3 shows our coding of cases in which suicidal 
and self injurious behaviours were considered.
analysis of harms data
In analysing the harms data for the safety population, 
we firstly explored the discrepancies in the number of 
events between case report forms and the CSR. Sec-
ondly, we presented all adverse events rather than those 
happening only at a particular rate (as done by Keller 
and colleagues). Thirdly, we grouped events into 
broader system organ class (SOC) groups: psychiatric, 
cardiovascular, gastrointestinal, respiratory, and other. 
Table D in appendix 2 summarises all adverse events by 
all MedDRA SOC groupings. Fourthly, we broke down 
events by severity, selecting adverse events coded as 
severe and using the listing in appendix G of the CSR of 
patients who discontinued for any reason. Fifthly, we 
included an analysis of the effects of previous treatment, 
presenting the run-in phase profiles of drugs taken by 
patients entering each of the three arms of the study and 
comparing the list of adverse events experienced by 
patients on concomitant drugs (from appendix B) versus 
those not on other drugs. Finally, we extracted the 
events occurring during the taper and follow-up phase.
We did not undertake statistical tests of harms data, 
as discussed below.
Patient withdrawal
A study patient could withdraw or be withdrawn prema-
turely for “adverse experiences including intercurrent 
illness,” “insufficient therapeutic effect,” “deviation from 
protocol including non-compliance,” “loss to follow-up,” 
“termination by SB [SKB],” and “other (specify).”
The CSR states that the primary reason for with-
drawal was determined by the investigator. We reviewed 
the codes given for discontinuation from the study, 
which are found in appendix G of the CSR, and we made 
changes in a proportion of cases.
statistical methods
The primary population of interest was the intention to 
treat population that included all patients who received 
at least one dose of study drug and had at least one 
assessment of efficacy after baseline. The demographic 
characteristics, description of the baseline depressive 
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episode, additional psychiatric diagnoses, and per-
sonal history variables of the patients were summarised 
descriptively by treatment group.
The acute phase eight week endpoint was our primary 
interest. Statistical conclusions concerning the efficacy 
of paroxetine and imipramine were made by using data 
obtained from the last observation carried forward (that 
is, the last assessment “on therapy” during the acute 
phase) and observed case datasets. Paroxetine and imip-
ramine were each to be compared with placebo; there 
was to be no comparison of paroxetine with imipramine.
We followed the methods of the a priori 1994 study 
protocol (amended in 1996 to accept a reduced sample 
size). It did not provide explicit statistical hypotheses 
(null hypotheses and alternative hypotheses); nor were 
there justifications for the proposed statistical 
approaches or statistical assumptions underlying them.
One of the two primary efficacy variables, proportion 
of responders (response), and one secondary efficacy 
variable, proportion of patients relapsing, were treated 
as categorical variables. The second primary efficacy 
variable, change in total HAM-D score over the acute 
phase, and the remaining secondary efficacy variables 
were treated as continuous variables.
In accordance with the protocol, the continuous 
 variables were analysed with parametric analysis of 
variance (ANOVA) with effects in the model including 
treatment, investigator, and treatment by investigator 
interaction. Pairwise comparisons were not done if the 
omnibus (overall) ANOVA was not significant (two 
sided P<0.05), as specified by the protocol (we acknowl-
edge differing opinions about this issue in the statistical 
literature,23  so we included them in table A in appendix 2, 
for completeness). The categorical variables were anal-
ysed with logistic regression, with the same effects 
included. In either case, if the treatment by investigator 
interaction resulted in a two sided P>0.10, the interac-
tion term was dropped from the model. Statistical 
 testing was done with the linear model (LM) and gen-
eral linear models (GLM) procedures of the R statistical 
package (version 2.15.2) as provided by GSK. Imputation 
was performed with the multiple imputation by chained 
equations (MICE) package also in R.24
For the analyses of relapse rates, we included all 
responders (HAM-D ≤8 or ≥50% reduction in symptoms) 
who met the original criteria for entry to the continua-
tion phase of the study. Patients were considered to have 
relapsed if they no longer met the responder criteria or if 
they were withdrawn for “intentional overdose.”
Results
Table 1 shows the demographics of the groups, along 
with depression parameters, comorbidities, and base-
line scores for the efficacy variables.
Figure 1 summarises the allocations and discontinua-
tions among the three treatment groups during the acute 
study period. The flow chart covers the intention to treat 
population for the acute phase and the efficacy analysis. 
The paroxetine group was titrated to a dose of 20 mg/day 
by week four, with 55% (51/93) of participants moving to 
a higher dose (mean 28.0 mg/day, SD 8.4 mg) by week 
eight. The imipramine group was titrated to 200 mg/day 
by week four, with 40% (38/95) moving to a higher dose 
(mean 205.8 mg/day, SD 63.9 mg) by week eight. Twenty 
eight patients reached the highest permissible dose of 
40 mg of paroxetine, and 20 patients were titrated to the 
maximum 300 mg of imipramine.
efficacy
There were no discrepancies between any of our 
 analyses and those contained in the CSR. Figures 2 and 3 
illustrate the longitudinal values for the two primary 
efficacy variables: mean change from baseline in the 
HAM-D score and the percentage responding, defined as 
a decrease in HAM-D score by 50% or more from base-
line or a final HAM-D score of ≤8. The difference between 
paroxetine and placebo fell short of the prespecified 
level of clinical significance (4 points) and neither pri-
mary outcome achieved significance at any measured 
interval for any dataset during the acute phase.
The formal reanalysis included both observed case 
and last observation carried forward datasets. As men-
tioned above, the multiple imputation dataset is 
included for comparison. There was no statistical 
 significance (considered at P<0.05) or clinical signifi-
cance shown for any of the prespecified primary or 
 secondary efficacy variables in either the observed case 
or last observation carried forward datasets, so pairwise 
analysis was considered unjustified. Table 2 shows the 
results at week eight for reduction in HAM-D score and 
for the proportion of patients who met criteria for 
HAM-D response. 
table 1 | baseline characteristics of groups in study 329
Paroxetine (n=93) imipramine (n=95) Placebo (n=87)
Mean (SD) age (years) 14.8 (1.6) 14.9 (1.6) 15.1 (1.6)
Sex (male/female) 35/58 39/56 30/57
No (%) by race:
 White 77 (83) 83 (87) 70 (81)
 African American 5 (5) 3 (3) 6 (7)
 Asian American 1 (1) 2 (2) 2 (2)
 Other 10 (11) 7 (7) 9 (10)
Depression:
 Mean (SD) duration of episode (months) 14 (18) 13 (17) 13 (17)
 Mean (SD) age at first episode (years) 13.1 (2.8) 13.7 (2.7) 13.5 (2.3)
 No (%) of previous episodes:
  0 0 (0) 2 (2) 0 (0)
  1 75 (81) 75 (79) 68 (77)
  2 11 (12) 13 (14) 12 (14)
  >3 7 (7) 5 (6) 7 (8)
No (%) with comorbidity:
 Any comorbid disorder * 42 (41) 47 (50) 39 (41)
 Current anxiety disorder* 24 (19) 24 (26) 24 (19)
 ODD, CD, or ADHD* 23 (25) 24 (26) 17 (20)
Least squares mean baseline scores (SEM):
 HAM-D 18.9 (0.44) 18.1 (0.43) 19.0 (0.44)
 K-SADS-L 28.3 (9.5) 27.5 (0.51) 28.3 (0.52)
 Autonomous function 93.4 (3.1) 97.0 (3.1) 94.2 (3.2)
 Self perception profile 64.0 (2.2) 63.5 (2.2) 63.4 (2.3)
 Sickness impact profile 32.4 (1.2) 30.8 (1.2) 32.9 (1.3)
ODD=oppositional defiant disorder, CD=conduct disorder, ADHD=attention-deficit/hyperactivity disorder, 
HAM-D=Hamilton depression scale, K-SADS-L=affective disorders and schizophrenia for adolescents-lifetime 
version, SD=standard deviation, SEM=standard error of mean.
*From K-SADS-L structured interview at screening.
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HAM-D scores decreased by 10.7 (95% confidence 
interval 9.1 to 12.3), 9.0 (7.4 to 10.5), and 9.1 (7.5 to, 10.7) 
points (least squares mean) for the paroxetine, imipra-
mine, and placebo groups, respectively. 
Table 3 shows the results at eight weeks for the sec-
ondary efficacy variables. 
Although the protocol listed “predictors of response” 
among the secondary efficacy variables, the absence of 
statistically or clinically significant differences among 
the three arms rendered this analysis void.
The protocol also listed the relapse rate in the contin-
uation phase for responders as a secondary outcome 
variable. Our calculation differed from that in the CSR 
because we included those whose HAM-D scores rose 
above the “response” range and those who intention-
ally overdosed. In the continuation phase, the dropout 
rates were too high in all groups for any precise inter-
pretation: 33/51 (65%) in the paroxetine group; 25/39 
(64%) in the imipramine group; and 21/34 (62%) in the 
placebo group. The recorded relapses were 25/51 (49%), 
16/39 (41%), and 12/34 (35%), respectively. Although the 
relapse rate was lower in the placebo group, the differ-
ences were not significant (2×3 χ2 P=0.44).
Harms
Review of case report forms
We reviewed case report forms in appendix H for 93 
(34%) of 275 patients. We discovered adverse events 
recorded onto case report forms but not transcribed into 
the patient level listings of adverse events in appendix D 
of the CSR. Table 4 shows these discrepancies. The most 
common categories of additional adverse events found 
in case report forms were psychiatric for paroxetine 
(12/23) and placebo (4/10) and cardiovascular for imip-
ramine (5/17) (table B in appendix 2).
Randomised (n=275)
Paroxetine
Randomised (n=93)
Analysed (n=90)
Imipramine
Randomised (n=95)
Analysed (n=94)
Placebo
Randomised (n=87)
Analysed (n=87)
Paroxetine
8 weeks (n=67; 72%)
Imipramine
8 weeks (n=56; 59%)
Placebo
8 weeks (n=66; 76%)
Paroxetine
32 weeks (n=51; 55%)
Imipramine
32 weeks (n=39; 41%)
Placebo
32 weeks (n=34; 39%)
Acute phase discontinuation (n=26):
  Adverse events (n=13)
  Lack of ecacy (n=3)
  Protocol violations (n=1)
  Lost to follow-up (n=4)
  Withdrawn consent (n=5)
Acute phase discontinuation (n=39):
  Adverse events (n=31)
  Lack of ecacy (n=0)
  Protocol violations (n=6)
  Lost to follow-up (n=1)
  Withdrawn consent (n=1)
Acute phase discontinuation (n=21):
  Adverse events (n=6)
  Lack of ecacy (n=4)
  Protocol violations (n=9)
  Lost to follow-up (n=1)
  Withdrawn consent (n=1)
Post-acute discontinuation (n=16):
  Adverse events (n=5)
  Lack of ecacy (n=5)
  Protocol violations (n=2)
  Lost to follow-up (n=1)
  Withdrawn consent (n=2)
  HAM-D responder (n=1)
Post-acute discontinuation (n=17):
  Adverse events (n=4)
  Lack of ecacy (n=8)
  Protocol violations (n=4)
  Lost to follow-up (n=0)
  Withdrawn consent (n=0)
  HAM-D responder (n=1)
Post-acute discontinuation (n=32):
  Adverse events (n=0)
  Lack of ecacy (n=17)
  Protocol violations (n=4)
  Lost to follow-up (n=0)
  Withdrawn consent (n=5)
  HAM-D responder (n=6)
Fig 1 | group allocations and discontinuations in trial of paroxetine and imipramine in treatment of major depression in 
adolescence
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Fig 2 | Differences in HaM-D scores in study of efficacy and 
harms of paroxetine and imipramine in treatment of major 
depression in adolescence (table 2 shows numerical 
values). Points are least squares means (95% Ci). 
lOCF=last observation carried forward, Mi=multiple 
imputation
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Fig 3 | Differences in HaM-D % responders in study of 
efficacy and harms of paroxetine and imipramine in 
treatment of major depression in adolescence (table 2 
shows numerical values). lOCF=last observation carried 
forward, Mi=multiple imputation
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Coding and representation of adverse event data
Table 5 presents the number of adverse events found in 
this study summarised by system organ class (SOC), 
firstly as coded by SKB using ADECS, secondly as 
reported by Keller and colleagues (who reported only 
adverse events that occurred at frequency of more than 
5%), and thirdly as coded by us using MedDRA. Some 
adverse events always fall within a particular system 
organ class; others require that the coder choose 
between system organ classes. A full listing of adverse 
events can be found in table E in appendix 2.
We included events occurring during the taper 
phase that SKB allocated to the continuation phase as 
acute phase adverse events. In a study that has a con-
tinuation phase, the assessment of adverse events 
throws up a methodological difficulty not yet 
addressed by groups such as CONSORT. If a study has 
only an acute phase, then all adverse events are 
counted for all patients receiving treatment as well as 
in any taper phase, and often for a 30 day follow-up 
period. When a study has a continuation phase, the 
taper and 30 day follow-up periods are displaced. To 
ensure comparable analysis of all participants, we tal-
lied the adverse events across the acute phase and 
both taper and follow-up phases, whether displaced or 
table 2 | Datasets for primary efficacy variables at eight weeks and proportion of patients who met criteria for HaM-D response >50% drop or <8 in study 
329 for observed cases (OC), last observation carried forward (lOCF), and multiple imputation
Data Paroxetine imipramine Placebo P value
HaM-D change
least squares mean (95% Ci), seM
no of 
patients
least squares mean 
(95% Ci), seM
no of 
patients least squares mean (95% Ci), seM
no of 
patients anCOva*
OC −12.2 (−13.1 to −10.5), 0.88 67 −10.6 (−12.5 to −8.7), 0.97 56 −10.5 (−12.3 to −8.8), 0.88 66 0.26
LOCF −10.7 (−12.3 to −9.1), 0.81 90 −9.0 (−10.5 to −7.4), 0.81 94 −9.1 (−10.7 to −7.5), 0.83 87 0.20
MI −12.5 (−14.2 to −10.9), 0.83 90 −11.1 (−12.9 to −9.4), 0.89 94 −10.7 (−12.4 to −9.1), 0.83 87 0.24
HaM-D response (>50% reduction or <8)
Criteria met Yes/no Criteria met Yes/no Criteria met Yes/no χ2
OC 80.6% 54/13 73.2% 41/15 65.2% 43/23 0.13
LOCF 66.7% 60/30 58.5% 55/39 55.2% 48/39 0.27
MI 73.3% 66/24 70.2% 66/28 70.1% 61/26 0.24
HAM-D=Hamilton depression scale.
*All P values uncorrected for multiple variable sampling.
table 3 | Datasets for secondary efficacy variables at eight weeks in study 329 for observed cases (OC), last observation carried forward (lOCF), and 
multiple imputation
Data
Paroxetine imipramine Placebo
P value*
least squares mean 
(95% Ci) seM
no of 
patients
least squares mean 
(95% Ci) seM
no of 
patients
least squares mean 
(95% Ci) seM
no of 
patients
K-SADS-L change
 OC −12.1 (−13.8 to −10.3) 0.91 67 −10.7 (−12.7 to −8.7) 0.82 56 −10.7 (−12.5 to −8.9) 0.92 65 0.46
 LOCF −11.4 (−13.1 to −9.8) 0.84 83 −9.5 (−11.1 to −7.9) 0.82 88 −9.4 (−11.0 to −7.8) 0.83 85 0.13
 MI −12.3 (−13.9 to −10.6) 0.84 83 −11.5 (−13.3 to −9.7) 0.91 88 −10.9 (−12.6 to −9.2) 0.86 85 0.45
Clinical global impression mean score
 OC 1.9 (1.6 to 2.2) 0.15 68 2.2 (1.8 to 2.5) 0.17 56 2.4 (2.1 to 2.7) 0.16 66 0.09
 LOCF 2.4 (2.1 to 2.7) 0.16 90 2.7 (2.4 to 3.0) 0.15 94 2.7 (2.4 to 3.0) 0.16 87 0.16
 MI 1.9 (1.6 to 2.2) 0.14 90 2.2 (1.9 to 2.5) 0.15 94 2.4 (2.1 to 2.6) 0.14 87 0.07
Autonomous function check list change
 OC 14.4 (8.8 to 19.9) 2.83 58 13.3 (7.3 to 19.4) 3.04 52 9.3 (3.8 to 14.8) 2.81 60 0.32
 LOCF 14.7 (9.2 to 20.2) 2.80 60 11.6 (5.8 to 17.3) 2.92 57 9.3 (8.1 to 17.2) 2.76 62 0.39
 MI 14.0 (8.7 to 19.3) 2.65 60 14.5 (9.4 to 19.6) 2.60 57 9.1 (4.2 to 14.1) 2.52 62 0.24
Self perception profile change
 OC 12.9 (8.3 to 17.5) 2.31 60 13.2 (8.4 to 18.1) 2.46 55 12.7 (6.9 to 15.9) 2.30 60 0.88
 LOCF 13.2 (8.6 to 17.8) 2.33 61 13.1 (8.3 to 17.8) 2.41 60 11.4 (6.9 to 15.9) 2.27 63 0.88
 MI 15.4 (10.7 to 20.0) 2.35 61 14 (8.9 to 19.2) 2.60 60 14.7 (10.0 to 19.4) 2.39 63 0.92
Sickness impact profile change
 OC −11.2 (−14.3 to −8.1) 1.57 62 −13.5 (−16.9 to −10.2) 1.70 55 −10.6 (−13.7 to −7.5) 1.57 62 0.24
 LOCF −11.4 (−14.4 to −8.3) 1.55 63 −13.0 (−16.2 to −9.8) 1.62 60 −9.9 (−12.9 to −6.9) 1.51 65 0.23
 MI −11.5 (−14.2 to −8.7) 1.39 63 −13.9 (−16.8 to −10.9) 1.50 60 −10.1 (−13.0 to −7.1) 1.48 65 0.19
K-SADS-L=affective disorders and schizophrenia for adolescents-lifetime version.
*ANCOVA. All P values uncorrected for multiple variable sampling.
table 4 | adverse events found in case report forms (CrFs) compared with adverse events 
listed in appendix D of clinical study report of study 329
Paroxetine 
(n=31)
imipramine* 
(n=40)
Placebo 
(n=22)
Adverse events found in CRFs (appendix H) 159 257 77
Adverse events found in appendix D 136 240 67
% underestimate in relying only on appendix D 14% 7% 13%
*In considering adverse effects from imipramine, it should be noted that doses (mean 205.8 mg) were high for 
adolescents. In six comparator studies submitted by SKB as part of their 1991 approval NDA for paroxetine in 
adults, mean imipramine dose overall was 140 mg, with mean endpoint dose of 170 mg.25
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not. SKB do not seem to have done this, leading to 
some differences in numbers.
Figure 4 shows when suicidal and self injurious 
events occurred.
Table 6 shows the numbers of suicidal and self-in-
jurious behaviours that we identified in our RIAT 
analysis and compared with what was reported by 
Keller and colleagues and documented in the CSR 
(table 6).
The full details for patients included in this table can 
be found in appendix 3, along with working notes and 
directions to where in the CSR the key details can be 
found. It is possible to take different approaches to 
moving taper phase events into the continuation phase 
and reviewing the coding for all cases, especially cases 
039, 089, and 106, that were designated suicidal and 
self injurious behaviours in the RIAT recoding. This 
would result in different figures.
There were no noteworthy changes in physiological 
data, which are detailed in appendix F (patient data 
listings of laboratory tests) in the CSR.
severity ratings
In the CSR, serious adverse events (defined as an event 
that “resulted in hospitalization, was associated with 
suicidal gestures, or was described by the treating phy-
sician as serious”) were reported in 11 patients in the 
paroxetine group, five in the imipramine group, and 
two in the placebo group. Designating an adverse event 
as serious hinged on the judgment of the clinical inves-
tigator. We were therefore unable to make comparable 
judgments of seriousness, but there are two other meth-
ods to approach the issue of severity of adverse events. 
One is to look at those rated as severe rather than mod-
erate or mild at the time of the event (table 7). A high 
number and proportion of severe psychiatric events 
occurred in the paroxetine group. In contrast, few of the 
table 5 | adverse events in sKb clinical study report (Csr) (aDeCs coded), Keller and colleagues (aDeCs coded), and riat 
reanalysis (MedDra coded) in study 329
adverse event (system organ class)
Paroxetine (n=93) imipramine (n=95) Placebo (n=87)
Csr* Keller* riat† Csr* Keller* riat† Csr* Keller* riat†
Cardiovascular 7 5 44 60 42 130 12 6 32
Gastrointestinal/digestive 80 84 112 108 106 147 59 61 79
Psychiatric — — 103 — — 63 — — 24
Respiratory 39 33 42 32 27 22 43 37 39
Neurological/nervous system 106 115 101 117 135 114 42 65 77
Other 121 28 79 51 30 76 30 38 79
Body as whole 106 — — 125 — — 121 — —
Total 338 265 481 493 340 552 277 207 330
*Coded with ADECS (adverse drug events coding system). While in CSR (table 14.2.1—it is not clear whether this includes taper phase), headaches were 
included in “body as whole”; in paper by Keller and colleagues, adverse events “headache” and “dizziness” were grouped with psychiatric adverse 
events under heading “nervous system.” 
†Coded with MedDRA. MedDRA allows dizziness to be coded under “cardiovascular” or “neurological” SOCs and puts headaches under “neurological” 
SOC. See also tables D and E in appendix 2.
Week
RIAT
0 4 8
End of
acute study
12 16 20
Imipramine
Placebo
Paroxetine
SKB
Imipramine
Placebo
Paroxetine
KELLER
Imipramine
Placebo
Paroxetine
On drugs On taper
Denite Possible
Fig 4 | timing of suicidal and self injurious events in study 
329, Keller and colleagues, and riat analysis
table 6 | numbers of patients with suicidal and self injurious behaviours in study 329 
with different safety methods
Paroxetine (n=93) imipramine (n=95) Placebo (n=87)
Keller and colleagues* 5 3 1
SKB acute from CSR* 7 3 1
RIAT acute and taper from CSR 11 4 (3 definite, 1 possible) 2 (1 definite, 1 possible)
*Keller and colleagues and CSR mostly reported suicide related events as “emotional lability.”
table 7 | adverse events (aDeCs coded) deemed serious by 
investigator in study 329 and reorganised by riat analysis 
to MeDra system organ class (sOC)
adverse event 
(system organ class)
Paroxetine 
(n=93)
imipramine 
(n=95)
Placebo 
(n=87)
Cardiovascular 1 3 0
Gastrointestinal 25 20 4
Psychiatric 32 4 6
Respiratory 2 1 4
Neurological 7 14 7
Other 3 8 5
Total 70 50 26
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many cardiovascular events in the imipramine group 
were rated as severe.
Discontinuations
A second method of approaching the issue of severity of 
adverse events is to look at rates of discontinuation 
because of such events. Table 8 shows reasons for 
 withdrawal during the acute phase and taper because 
of adverse events and other causes. Note that we 
 examined the case report forms from appendix H for all 
discontinuations reported in appendix G of the CSR. All 
changes of coding for discontinuation are laid out in 
table H in appendix 2.
Consideration of the displaced taper in Study 329 
revealed a conundrum. In addition to the 86 dropouts 
from the acute phase noted by SKB, there were 65 drop-
outs after ratings were completed at week eight. SKB 
regarded these patients as participants in the 
 continuation phase, although none of them took a 
 continuation phase drug or had a continuation phase 
rating. The coding for discontinuation was particularly 
ambiguous for this group.
Most patients stopped at this point were designated 
by SKB as “lack of efficacy” (table 9). Investigators in 
four centres reported lack of efficacy as a reason for 
stopping six patients allocated to placebo even though 
the HAM-D score was in the responder range and was as 
low as 2 or 3 points in some instances.
In some cases there were clear protocol violations or 
factors such as the unavailability of further treatments 
(placebo in particular). We recategorised the lack of effi-
cacy dropouts based on factors such as adverse events 
and HAM-D scores. Table 9 shows our analysis of rea-
sons for withdrawal at the end of the acute phase.
Withdrawal effects
The protocol for Study 329 called for a taper phase for 
all participants and, in addition, a 30 day follow-up 
period for all those who discontinued because of 
adverse events. The data in the appendix D of the CSR 
make it possible to identify adverse events happening 
in the taper and follow-up periods. These data are pre-
sented in table 10. 
effects of other drugs
Table 11 shows data on the effects of other drugs on the 
adverse events recorded. Patients taking other drugs 
had more adverse events than those who were not. This 
effect was slightly more marked in the placebo group, 
and as such works to the apparent benefit of the active 
drug treatments in minimising any excess of adverse 
events over placebo.
discussion
Principal findings and comparison with original 
journal publication
Our RIAT analysis of Study 329 showed that neither par-
oxetine nor high dose imipramine was effective in the 
treatment of major depression in adolescents, and there 
was a clinically significant increase in harms with both 
drugs. This analysis contrasts with both the published 
conclusions of Keller and colleagues2 and the way that 
the outcomes were reported and interpreted in the CSR.
We analysed and reported Study 329 according to 
the  original protocol (with approved amendments). 
 Appendix 1 shows the sources of information we used in 
preparing this paper, which should help other research-
ers who want to access the data to check our analysis or 
to interrogate it in other ways. We draw minimal conclu-
sions regarding efficacy and harms, inviting others to 
offer their own analysis.
Our re-examination of the data, including a review of 
34% of the cases, showed no significant discrepancies in 
the primary efficacy data. The marked difference 
between the efficacy outcomes as reported by us and 
those reported by SKB results from the fact that our anal-
ysis kept faith with the protocol’s methods and its desig-
nation of primary and secondary outcome  variables.
The authors/sponsors departed from their study 
 protocol in the CSR itself by performing pairwise 
table 8 | reasons for withdrawal (86 patients) during acute phase and taper* in 
study 329
reason for withdrawal
Paroxetine (n=93) imipramine (n=95) Placebo (n=87)
Csr riat Csr riat Csr riat
adverse event
Aggression 1 0 0 1 0 0
Mania 1 2 0 0 0 0
Overdose 1 1 0 0 0 0
Depression worsening 0 1 0 0 0 1
Agitation 0 1 0 0 0 0
Suicidality 0 5† 0 2 0 1
Hallucinations 0 0 0 1 0 0
Conduct disorder 1 1 0 0 0 0
Hospital admission/surgery 1 0 1 0 0 0
Fatigue 0 0 1 1 0 0
Sedation 0 1 0 1 0 0
Nausea/vomiting 0 1 2 5 0 1
Rash/acne 0 0 2 3 1 1
Cardiac 0 1 9 15 3 2
Accidental injury 0 0 1 0 0 0
Urinary 0 0 1 1 0 0
Pregnancy 0 0 1 1 0 0
Intercurrent illness‡ 6 0 12 0 2 0
Total adverse events (%) 11 (11.8) 14 (15.0) 30 (31.5) 31 (32.6) 6 (6.9) 6 (6.9)
Protocol violation§
Non-compliance with 
medication
3 1 4 4 6 4
By investigator 0 0 0 0 0 4
Recreational drug use 0 0 1 1 1 1
Total protocol violations (%) 3 (3.2) 1 (1.1) 5 (5.3) 5 (5.3) 7 (8.0) 9 (10.3)
Other (%)
Lost to follow-up 5 (5.4) 4 (4.3) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1)
Lack of efficacy 3 (3.2) 3 (3.2) 1 (1.1) 0 (0) 6 (6.9) 4 (4.6)
Withdrawn consent 4 (4.3) 5 (5.4) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1)
Overall
Total dropout rate (%) 26 (28) 27 (29) 38 (40) 38 (40) 21 (24) 21 (24)
*Reported in appendix G (tabulations by patient) from CSR and from appendix H CRFs.
†Patient 329.002.00058 was found to have stopped drug three days before attempting suicide. Originally this 
had been classed as “continuation phase” drop out, but we moved it to “30 day discontinuation” period. Reason 
for withdrawal was originally “adverse event including intercurrent illness” but we changed it to “suicide 
attempt.” Consequently RIAT analysis found total of 86 withdrawals rather than 85 reported in CSR.
‡We replaced term “adverse event: intercurrent illness” with more specific adverse event terms.
§Four patients enrolled in study violated inclusion criterion. Two had cardiovascular problems, one had C-GAS 
score >60, and one was “extremely” suicidal at screening. All four were randomised to placebo. It was unclear 
how to categorise their reasons for discontinuation; we chose “protocol violations.”
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table 10 | adverse events from taper phase of study 329 according to riat (reanalysis study)*
system organ class (MedDra)
Paroxetine (n=19) imipramine (n=32) Placebo nn=9)
riat MedDra 
coded
reported 
as severe
riat MedDra 
coded
reported 
as severe
riat MedDra 
coded
reported 
as severe
Cardiovascular disorders 4 0 9 0 0 0
Gastrointestinal disorders 9 4 18 4 4 0
Psychiatric disorders 15 8 2 0 1 1
Respiratory-thoracic disorders 3 0 1 0 0 0
All other SOCs 16 1 20 5 5 0
Total adverse events 47 13 50 9 10 1
*SKB did not present ADECS analysis for taper phase in clinical study report.
table 11 | use of other drugs in month before enrolment, and incidence of adverse events in study 329
Paroxetine (n=93) imipramine (n=95) Placebo (n=87)
Other 
drugs
no other 
drugs
Other 
drugs
no other 
drugs
Other 
drugs
no other 
drugs
No (%) of patients 24 (26) 69 (74) 31 (33) 64 (67) 26 (30) 61 (70)
Psychiatric adverse events subgroup* (acute+taper) 15 42 12 21 6 11
Total adverse events (acute+taper) 158 323 220 332 137 193
*Psychiatric adverse events included in this subgroup include: abnormal dreams, aggravated depression, agitation, akathisia, anxiety, 
depersonalisation, disinhibition, hallucinations, paranoia, psychosis, suicidal ideation/gesture/attempt.
table 9 | reasons for withdrawal (65 patients) at end of acute phase according to sKb and riat reanalysis in study 329*
reason for withdrawal
Paroxetine group  
(acute completers n=67)
imipramine group  
(acute completers n= 56)
Placebo group  
(acute completers n=66)
Csr, appendix g riat† Csr, appendix g riat† Csr, appendix g riat†
adverse event
Aggression/paranoia 1 1 0 0 0 0
Overdose 1 0 0 0 0 0
Depression worsening 0 1 0 0 0 0
Homicidal ideation 0 0 1 1 0 0
Suicidality 0 2 0 0 0 0
Rash 1 1 0 0 0 0
Cardiac 0 0 1 2 0 0
Dry mouth 0 0 0 1 0 0
Total adverse events 3 5 2 4 0 0
Protocol violation
Non-compliance with study treatment 1 1 2 2 0 0
Recreational drug use 0 0 0 0 1 1
PV by investigator 0 1 0 2 0 3
Total protocol violations 1 2 2 4 1 4
lost to follow-up
Total 0 2 0 0 0 0
lack of efficacy
Total 9 5 12 8 23 17
Withdrawn consent
Total 1 1 0 0 4 5
Other
HAM-D responders 0 1 0 1 0 6
General surgery 1 0 0 0 0 0
No study drugs available 1 0 0 0 3 0
ADHD symptoms 0 0 1 0 0 0
Moved out of state 0 0 0 0 1 0
Total “other” dropouts 2 1 1 1 4 6
Overall total
Total 16 16 17 17 32 32
HAM-D=Hamilton depression scale, ADHD=attention-deficit/hyperactivity disorder.
*Total discontinued at week 8 (end of acute phase). CSR and paper by Keller and colleagues report 86 patients who withdrew in acute phase, but are 
silent about these 65 patients who dropped out at end of acute phase.
†After review of reasons for withdrawal from study in the CSR (appendix G), along with review of patient narratives and CRFs where applicable, we 
proposed changes to these reasons for withdrawal in a proportion of those discontinued.
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 comparisons of two of the three groups when the omni-
bus ANOVA showed no significance in either the contin-
uous or dichotomous variables. They also reported four 
other variables as significant that had not been men-
tioned in the protocol or its amendments, without any 
acknowledgment that these measures were introduced 
post hoc. This contravened provision II of appendix B of 
the Study 329 protocol (“Administrative Matters”), 
according to which any change to the study protocol was 
required to be filed as an amendment/modification.
With regard to adverse events, there were large and 
clinically meaningful differences between the data as 
analysed by us, those summarised in the CSR using the 
ADECS methods, and those reported by Keller and col-
leagues. These differences arise from inadequate and 
incomplete entry of data from case report forms to sum-
mary data sheets in the CSR, the ADECS coding system 
used by SKB, and the reporting of these data sheets in 
Keller and colleagues. SKB reported 338 adverse events 
with paroxetine and Keller and colleagues reported 265, 
whereas we identified 481 from our analysis of the CSR, 
and we found a further 23 that had been missed from 
the 93 case report forms that we reviewed. 
Another reason why the figures of Keller and col-
leagues are lower than ours is because they presented 
data only for adverse events reported for 5% of patients 
or more. For all adverse events combined, their table 3 
reported a burden of adverse events with paroxetine 1.2 
times that of the burden with placebo. This compares 
with the figure of 1.4 from our RIAT MedDRA coding of 
data from the CSR. The figures from CSR and case report 
forms also differ substantially from other figures quoted 
by Keller and colleagues because they did not report a 
category of psychiatric adverse events, but instead 
grouped such events together with “dizziness” and 
“headache” under the class “nervous system.”
MedDRA distinguishes between neurological and 
psychiatric system organ classes. We placed headaches 
in the neurological rather than the psychiatric class. 
MedDRA allows dizziness to be coded under cardiovas-
cular or neurological classes.  Given the dose of imipra-
mine being used, most cases of dizziness seem likely to 
be cardiovascular, with Keller and colleagues also 
reporting a high rate of postural hypotension on imipra-
mine. We have thus coded all dizziness under cardio-
vascular rather than neurological. There is scope for 
others accessing the data to parse out whether there is 
sufficient information to code certain instances of dizzi-
ness, such as dizziness during paroxetine taper, as neu-
rological, but we have not carried out that more 
complex analysis.
As reported by Keller and colleagues, dizziness and 
headache comprised 54 of 115 nervous system events in 
those taking paroxetine (47%), 83 of 135 events in those 
taking imipramine (62%), and 50 of 65 events in those 
taking placebo (77%). The effect of disentangling these 
two symptoms from psychiatric adverse events 
unmasks a clinically important difference in psychiatric 
adverse event profiles between paroxetine and placebo.
There was a major difference between the frequency 
of suicidal thinking and events reported by Keller and 
colleagues and the frequency documented in the CSR, 
as shown in table 6.
With regard to dropouts, Keller and colleagues stated 
that 69% of patients completed the acute phase. Only 
45%, however, went on to the continuation phase, 
which has not yet been subject to RIAT analysis.
Comparison with other studies
Our findings are consistent with those of other studies, 
including a recent examination of 142 studies of six psy-
chotropic drugs for which journal articles and clinical 
trial summaries were both available.26 27 Most deaths 
(94/151, 62%) and suicides (8/15, 53%) reported in trial 
summaries were not reported in journal articles. Only 
one of nine suicides in olanzapine trials was reported in 
published papers.
reporting of adverse events
Our reanalysis of Study 329 showed considerable varia-
tions in the way adverse events can be reported, demon-
strating several ways in which the analysis and 
presentation of safety data can influence the apparent 
safety of a drug. We identified the following potential 
barriers to accurate reporting of harms (summarised in 
box 2).
Use of an idiosyncratic coding system
The term “emotional lability,” as used in SKB’s adverse 
drug events coding system, masks differences in sui-
cidal behaviour between paroxetine and placebo.
Failure to transcribe all adverse events from clinical 
record to adverse event database
Our review of case report forms disclosed significant 
under-recording of adverse events.
Filtering data on adverse events through statistical 
techniques
Keller and colleagues (and GSK in subsequent corre-
spondence) ignored unfavourable harms data on the 
grounds that the difference between paroxetine and 
placebo was not statistically significant, at odds with 
the SKB protocol that called for primary comparisons to 
be made using descriptive statistics. In our opinion, sta-
tistically significant or not, all relevant primary and 
secondary outcomes and harms outcomes should be 
explicitly reported. Testing for statistical significance 
is most appropriately undertaken for the primary 
box 2 Potential barriers to accurate reporting of harms
•	Use of an idiosyncratic coding system
•	Failure to transcribe all adverse events from clinical record to adverse event database
•	Filtering data on adverse events through statistical techniques
•	Restriction of reporting to events that occurred above a given frequency in any one group
•	Coding event under different headings for different patients (dilution)
•	Grouping of adverse events
•	 Insufficient consideration of severity
•	Coding of relatedness to study medication
•	Masking effects of concomitant drugs
•	 Ignoring effects of drug withdrawal
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 outcome measures as study power is based on these. We 
have not undertaken statistical tests for harms as we 
know of no valid way of interpreting them. To get 
away from a dichotomous (significant/non-signifi-
cant) presentation of evidence, we opted to present all 
original and recoded evidence to allow readers their 
own  interpretation. The data presented in appendix 2 
and related worksheets lodged at www.Study329.org 
will, however, readily permit other approaches to data 
analysis for those interested, and we welcome other 
analyses.
Restriction of reporting to events that occurred above 
a given frequency in any one group
In the paper by Keller and colleagues, reporting only 
adverse events that occurred in more than 5% of 
patients obscured the harms burden. In contrast, we 
report all adverse events that have been recorded. These 
are available in table E in appendix 2.
Coding event under different headings for different 
patients (dilution)
The effect of reporting only adverse events that have a 
frequency of more than 5% is compounded when, for 
instance, agitation might be coded under agitation, anx-
iety, nervousness, hyperkinesis, and emotional lability; 
thus, a problem occurring at a rate of >10% could vanish 
by being coded under different subheadings such that 
none of these reach a threshold rate of 5%.
Aside from making all the data available so that oth-
ers can scrutinise it, one way to compensate for this 
possibility is to present all the data in broader system 
organ class groups. MedDRA offers the following higher 
levels: psychiatric, cardiovascular, gastrointestinal, 
respiratory, and other. In table E in appendix 2, the 
adverse events coded here under “other” are broken 
down under the additional MedDRA SOC headings, 
including general, nervous system, metabolic, and 
pregnancy.
Grouping of adverse events
Even when they are presented in broader system 
groups, grouping common and benign symptoms with 
more important ones can mask safety issues. For 
example, in the paper by Keller and colleagues, com-
mon adverse events such as dizziness and headaches 
are grouped with psychiatric adverse events in the 
“nervous system” SOC heading. As these adverse 
events are common across treatment arms, this group-
ing has the effect of diluting the difference in psychiat-
ric side effects between paroxetine, imipramine, and 
placebo.
We followed MedDRA in reporting dizziness under 
“cardiovascular” events and headache under “ner-
vous system.” There might be better categorisations; 
our grouping is provisional rather than strategic. In 
table E in appendix 2, we have listed all events coded 
under each system organ class heading, and we invite 
others to further explore these issues, including alter-
native higher level categorisation of these adverse 
events.
Insufficient consideration of severity
In addition to coding adverse events, investigators rate 
them for severity. If no attempt is made to take severity 
into account and include it in reporting, readers could 
get the impression that there was an equal burden of 
adverse events in each arm, when in fact all events in 
one arm might be severe and enduring while those in 
the other might be mild and transient.
One way to manage this is to look specifically at those 
patients who drop out of the study because of adverse 
events. Another method is to report those adverse 
events coded as severe for each drug group separately 
from those coded as mild or moderate. We used both 
approaches (see tables 7 and 8).
Coding of relatedness to study medication
Judgments by investigators as to whether an adverse 
event is related to the drug can lead to discounting the 
importance of an effect. We have included these judg-
ments in the worksheets lodged at www.Study329.org, 
but we have not analysed them because it became 
clear that the blinding had been broken in several 
cases before relatedness was adjudicated by the origi-
nal investigators and because some judgments were 
implausible. For instance, it is documented on page 
279 in the CSR that an investigator, knowing the 
patient was on placebo, declared that a suicidal event 
was “definitely related to treatment” on the grounds 
that “the worsening of depression and suicidal 
thought were life threatening and definitely related to 
study medication [known to be placebo] in that there 
was a lack of effect.” Notably, of the 11 patients with 
serious adverse events on paroxetine (compared with 
two on placebo) reported in the paper by Keller and 
colleagues, only one “was considered by the treating 
investigator to be related to paroxetine treatment,” 
thus dismissing the clinically important difference 
between the paroxetine and placebo groups for seri-
ous adverse events.
Masking effects of concomitant drugs
In almost all trials, patients will be taking concomitant 
drugs. The adverse events from these other drugs will 
tend to obscure differences between active drug treat-
ment and placebo. This might be an important factor in 
trials of treatments such as statins, where patients are 
often taking multiple drugs.
Accordingly, we also compared the incidence of 
adverse events in patients taking concomitant drugs 
with the incidence in those not taking other drugs. 
Other drugs were instituted in the course of the study 
that we have not analysed, but the data are available 
in tables K and L in appendix 2 and worksheets lodged 
at www.Study329.org and in appendix B from the CSR. 
There are several other angles in the data available at 
www.Study329.org that could be further explored, 
such as the effects of withdrawal of concomitant drugs 
on adverse event profiles, as the spreadsheets 
 document the day of onset of adverse events and the 
dates of starting or stopping any concomitant drugs. 
Another option to explore is the possibility of any 
the bmj | BMJ   2015;101hh; 2 | doi1 02.00;6/bmj.hh; 2
RESEARCH
15
 prescribing cascades triggered by adverse events 
related to study drugs.
Ignoring effects of drug withdrawal
The protocol included a taper phase lasting 7-17 days 
that investigators were encouraged to adhere to, even 
in patients who discontinued because of adverse 
events. The original paper did not analyse these data 
separately. The increased rates of psychiatric adverse 
events that emerged during the discontinuation phase 
in our analysis are consistent with dependence on 
and withdrawal from paroxetine, as reported by 
Fava.29
riat process
This RIAT exercise proved to be extremely demanding 
of resources. We have logged over 250 000 words of 
email correspondence among the team over two 
years. The single screen remote desktop interface 
(that we called the “periscope”) proved to be an enor-
mous challenge. The efficacy analysis required that 
multiple spreadsheet tables were open simultane-
ously, with much copying, pasting, and cross check-
ing, and the space was highly restrictive. Gaining 
access to the case report forms required extensive cor-
respondence with GSK.12 Although GSK ultimately 
provided case report forms, they were even harder to 
manage, given that we could see only one page at a 
time. It required about a thousand hours to examine 
only a third of the case report forms. Being unable to 
print them was a considerable handicap. There were 
no means to prepare packets for multiple indepen-
dent coders, to decrease bias; to make annotations or 
use margin comments; or to sort and collate the 
adverse event reports. Our experience highlights that 
hard copies as well as electronic copies are crucial for 
an enterprise like this.
Our analysis indicates that although CSRs are useful, 
and in this case all that was needed to reanalyse 
 efficacy, analysis of adverse events requires access to 
individual patient level data in case report forms.
Because we have been breaking new ground, we have 
not had precedents to call on in analysis and reporting. 
We await with interest other efforts to do something 
similar.
strengths and limitations of this study
Study 329 was a randomised controlled trial with a rea-
sonable sample size. There was, however, evidence of 
protocol violations, including some cases of breaking of 
blinding. The coding of adverse events by the original 
investigators raised the possibility that some other data 
might be unreliable.
The trial lasted for only eight weeks. Participants had 
relatively chronic depression (mean duration more than 
one year), which would limit the generalisability of the 
results, particularly in primary care, because many 
cases of adolescent depression have shorter dura-
tions.28 Generalisability to primary care would also be 
limited by the fact that participants were recruited 
through tertiary settings.
The RIAT analysis broke new ground but was limited 
in that we could check only 34% (93/275) of case report 
forms. Time and resources prevented access to all forms 
because of the difficulties in using the portal for access-
ing the study data and because considerable amounts 
of data were missing.
The analysis generated a useful taxonomy of poten-
tial barriers to accurate reporting of adverse events and, 
even allowing for the above limitations, showed the 
value of permitting access to data.
Conclusion and implications for research and policy
Contrary to the original report by Keller and colleagues, 
our reanalysis of Study 329 showed no advantage of 
paroxetine or imipramine over placebo in adolescents 
with symptoms of depression on any of the prespecified 
variables. The extent of the clinically significant 
increases in adverse events in the paroxetine and imip-
ramine arms, including serious, severe, and suicide 
related adverse events, became apparent only when the 
data were made available for reanalysis. Researchers 
and clinicians should recognise the potential biases in 
published research, including the potential barriers to 
accurate reporting of harms that we have identified. 
Regulatory authorities should mandate accessibility of 
data and protocols.
As with most scientific papers, Keller and colleagues 
convey an impression that “the data have spoken.” This 
authoritative stance is possible only in the absence of 
access to the data. When the data become accessible to 
others, it becomes clear that scientific authorship is 
provisional rather than authoritative.
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